Effect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study
Sponsored by Seoul National University Bundang Hospital
About this trial
Last updated a month ago
Study ID
B-2602-1024-103
Status
Recruiting
Type
Observational
Placebo
No
Accepting
19+ Years
All Sexes
Trial Timing
Started 4 months ago
What is this trial about?
This study aims to evaluate the clinical effectiveness of the oXiris® hemofilter in patients with septic shock and acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). While some studies suggest that oXiris® may improve hemodynamic stability by removing endotoxins and cytokines, its impact on survival remains inconsistent.To provide more reliable causal evidence, this multicenter retrospective cohort study utilizes a Target Trial Emulation (TTE) approach. The study will compare patients treated with the oXiris® filter to those treated with standard CRRT filters, focusing on in-hospital mortality and other clinical outcomes such as fluid balance and vasopressor requirements.
What are the participation requirements?
Inclusion Criteria
* Adults aged 19 years or older.
* Admitted to the ICU with septic shock (Sepsis-3 criteria) between March 2021 and August 2025.
* Required Continuous Renal Replacement Therapy (CRRT) due to acute kidney injury (AKI).
Exclusion Criteria
* Death or withdrawal of life-sustaining therapy within 48 hours of ICU admission.
* Patients with End-Stage Renal Disease (ESRD).
* Patients with missing critical covariates.